CAMP4 Therapeutics (NASDAQ:CAMP) Research Coverage Started at Needham & Company LLC

Needham & Company LLC initiated coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP) in a research report sent to investors on Thursday, Marketbeat.com reports. The firm issued a buy rating and a $8.00 target price on the Wireless communications provider’s stock.

Several other research analysts have also recently issued reports on CAMP. Cantor Fitzgerald reiterated an “overweight” rating on shares of CAMP4 Therapeutics in a report on Tuesday, September 29th. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Oppenheimer started coverage on CAMP4 Therapeutics in a research report on Monday, October 5th. They set an “outperform” rating and a $15.00 price target on the stock. Piper Sandler reissued an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research note on Friday, August 14th. Finally, Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $10.50.

CAMP4 Therapeutics Trading Down 8.1%

NASDAQ CAMP opened at $3.17 on Thursday. The business’s 50-day moving average price is $4.12 and its 200 day moving average price is $4.17. CAMP4 Therapeutics has a twelve month low of $2.86 and a twelve month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The business had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. As a group, research analysts anticipate that CAMP4 Therapeutics will post -0.66 earnings per share for the current year.

Insider Transactions at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, Director Richard A. Young bought 16,378 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average cost of $1.65 per share, with a total value of $27,023.70. Following the completion of the purchase, the director directly owned 186,388 shares in the company, valued at approximately $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CFO Kelly Gold bought 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were acquired at an average cost of $3.96 per share, with a total value of $39,600.00. Following the completion of the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $39,600. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Corporate insiders own 21.69% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CAMP. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth $78,000. Trails Edge Capital Partners LP acquired a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth $8,446,935. Jupiter Topco LLC acquired a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth $27,581,000. 5AM Venture Management LLC acquired a new stake in shares of CAMP4 Therapeutics during the second quarter worth $25,647,928. Finally, BlackRock Inc. acquired a new stake in shares of CAMP4 Therapeutics during the second quarter worth $7,185,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.